ST. LOUIS, Feb. 21 /PRNewswire-FirstCall/ -- GenoMed , a Next Generation Disease Management company whose business is public health, announced today that its first HIV patient had his viral load fall to zero after starting GenoMed’s trial.
The patient is a 54 year old African American man who was diagnosed with HIV 2 years ago. He was being treated with a standard triple-drug “cocktail” and had a stable viral load when he began GenoMed’s trial this past summer, as shown in the following table:
Date HIV viral load (copies of the virus per milliliter) 4/11/05 160 6/23/05 228 7/19/05 225 8/29/05 START OF GenoMed’s TRIAL 11/2005 0 12/2005 0 1/2006 Switch from Sustiva(R) to Kaletra(R), which had failed this patient in the past 2/14/06 109
Said Dr. David Moskowitz, GenoMed’s CEO and Chief Medical Officer, “In this trial, we’ve been using blood pressure pills, for which we have a ‘use’ patent that is pending. Why this should work is as interesting as the fact that it has worked. It points out the clinical reliability of the genomic epidemiologic data that we published in 2002.”
Continued Dr. Moskowitz, “Our approach, if it is confirmed in other HIV patients, may help with the chronic treatment of HIV patients. Our earlier data suggests that this approach may also decrease infectivity of the HIV virus in the first place. Because these drugs already are on the shelves in most pharmacies on earth, including Africa, it could be quite helpful in the global struggle against HIV/AIDS.”
About GenoMed
GenoMed’s broad-spectrum anti-viral approach is specifically mentioned in BioShield II, (see Section 2151 of Senate bill S. 975). GenoMed uses already existing, safe medication present in every drug store in the world. Anyone interested in participating in GenoMed’s clinical trial for HIV or other viral diseases, including avian influenza or regular influenza, should contact Dr. Moskowitz at dwmoskowitz@genomed.com.
Safe Harbor Statement
This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company’s) finances and treatments. The words or phrases “ought to,” “should,” “could,” “may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward- looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward- looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
GenoMed
CONTACT: David W. Moskowitz MD, CEO of GenoMed, +1-314-983-9933,dwmoskowitz@genomed.com
Web site: http://www.genomed.com/
